Avalon GloboCare (NASDAQ:CHGA) Announces Quarterly Earnings Results

Avalon GloboCare (NASDAQ:CHGA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($3.53) earnings per share for the quarter, FiscalAI reports.

Avalon GloboCare Stock Down 16.4%

Shares of NASDAQ:CHGA opened at $0.89 on Tuesday. The company’s fifty day moving average is $1.72 and its two-hundred day moving average is $6.98. Avalon GloboCare has a 12-month low of $0.69 and a 12-month high of $37.65. The company has a market cap of $992,656.00, a P/E ratio of -0.06 and a beta of -0.15.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Avalon GloboCare has an average rating of “Sell”.

Check Out Our Latest Report on Avalon GloboCare

Avalon GloboCare Company Profile

(Get Free Report)

Avalon GloboCare is a biotechnology and healthcare company whose activities have included developing cell-based therapies and precision diagnostic technologies. Its research has focused on applications in areas such as cancer and regenerative medicine. The company has worked on cell therapy approaches, including CAR-T and natural killer cell technologies, as well as diagnostic products and services. These activities have included research and development programs, rather than a broad portfolio of established therapies.

Read More

Earnings History for Avalon GloboCare (NASDAQ:CHGA)

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.